July 03, 2019
Article
The profound consequences of the results guide decisions about testing. Who should be tested? And, just as important, who should not?
The Success of the Jefferson Mobile Stroke Unit: Alvin Wang, DO, BC-EMS
Progress in Neurogenerative Disease Drug Development: Gregory A. Rippon, MD, MS
Diazepam Nasal Spray Significantly Extends Time Between Seizure Clusters
Reactions to FDA Advisory Panel Decision on AMX0035: Justin Klee; Josh Cohen, BSc